Market research
MEB.F MedinCell S.A
F EUR Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
Market facts
- Market cap
- 762M
- P/E ratio
- Not available
- Analyst target
- Not available
- Dividend yield
- Not available
- Beta
- 0.97
Profile
Company facts
- Exchange
- F
- Currency
- EUR
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- FR0004065605
- Market cap
- 762M
- P/E ratio
- Not available
- Analyst target
- Not available
- Dividend yield
- Not available
- Beta
- 0.97
About
About MedinCell S.A
MedinCell S.A. engages in the research and development of biodegradable polymer-based processes for the controlled and prolonged delivery of active pharmaceutical ingredients into the human body and animals in France. The company offers UZEDY, a subcutaneous risperidone for the treatment of schizophrenia. It also develops mdc-TJK, a subcutaneous injection, which is in NDA stage for the treatment of schizophrenia; and mdc-CWM, a sustained-release formulation of celecoxib, which is in Phase III clinical trial for the treatment and reduction of post-operative pain and inflammation. In addition, the company engages in the development of products in preclinical stage, including mdc-WWM for contraception; mdc-STM for the treatment of malaria; and mdc-AbbVie-1. It has strategic collaborations with TEVA, AIC, ABBVIE, Unitaid, and Gates Foundation. The company was incorporated in 2003 and is headquartered in Jacou, France.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the MEB.F discussion.
5 years, 5 months ago
MedinCell S.A is currently in a long term downtrend where the price is trading 15.3% below its 200 day moving average.
From a valuation standpoint, the stock is 91.5% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 111.9.
Finally, its free cash flow grew by 24.4% to $-3M since the same quarter in the previous year.
Based on the above factors, MedinCell S.A gets an overall score of 2/5.